Biondvax Pharmaceuticals Gross Profit

Biondvax Pharmaceuticals posts a gross profit of $2M as of June 2023. That compares with $2.7M in the prior-year period — down 26.6% year over year. That is below the Healthcare sector average of $67B. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Biondvax Pharmaceuticals's gross profit was $2.7M. The latest reading is $2M — a 26.6% year-over-year decrease (period ending June 2023). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a gross profit near $67B is typical. Biondvax Pharmaceuticals's $2M is lower that level. That is roughly 100.0% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Gross Profit is one piece of Biondvax Pharmaceuticals's financial statement story. At $2M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for BVXV's gross profit usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $67B), and (3) consistency with growth and profitability. This page covers the first two; Biondvax Pharmaceuticals's other metric pages and overview cover the third.